BlackRock’s iTeos Therapeutics ITOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-4,574,537
| Closed | -$45.6M | – | 5523 |
|
|
2025
Q2 | $45.6M | Buy |
4,574,537
+65,290
| +1% | +$526K | ﹤0.01% | 2502 |
|
|
2025
Q1 | $26.9M | Buy |
4,509,247
+707,738
| +19% | +$5.2M | ﹤0.01% | 2761 |
|
|
2024
Q4 | $29.2M | Sell |
3,801,509
-81,040
| -2% | -$696K | ﹤0.01% | 2803 |
|
|
2024
Q3 | $39.6M | Buy |
3,882,549
+151,513
| +4% | +$2.31M | ﹤0.01% | 2623 |
|
|
2024
Q2 | $55.4M | Sell |
3,731,036
-383,784
| -9% | -$5.5M | ﹤0.01% | 2351 |
|
|
2024
Q1 | $56.1M | Sell |
4,114,820
-146,925
| -3% | -$1.6M | ﹤0.01% | 2372 |
|
|
2023
Q4 | $46.7M | Sell |
4,261,745
-789,223
| -16% | -$7.82M | ﹤0.01% | 2515 |
|
|
2023
Q3 | $55.3M | Buy |
5,050,968
+370,774
| +8% | +$4.74M | ﹤0.01% | 2340 |
|
|
2023
Q2 | $62M | Buy |
4,680,194
+216,888
| +5% | +$3.09M | ﹤0.01% | 2356 |
|
|
2023
Q1 | $60.7M | Sell |
4,463,306
-16,115
| -0.4% | -$289K | ﹤0.01% | 2316 |
|
|
2022
Q4 | $87.5M | Buy |
4,479,421
+162,264
| +4% | +$3.17M | ﹤0.01% | 2086 |
|
|
2022
Q3 | $82.2M | Buy |
4,317,157
+595,920
| +16% | +$13.7M | ﹤0.01% | 2097 |
|
|
2022
Q2 | $76.7M | Buy |
3,721,237
+389,924
| +12% | +$9.25M | ﹤0.01% | 2201 |
|
|
2022
Q1 | $107M | Buy |
3,331,313
+1,718,085
| +106% | +$62.4M | ﹤0.01% | 2103 |
|
|
2021
Q4 | $75.1M | Buy |
1,613,228
+54,992
| +4% | +$1.83M | ﹤0.01% | 2393 |
|
|
2021
Q3 | $42.1M | Buy |
1,558,236
+41,498
| +3% | +$1.08M | ﹤0.01% | 2771 |
|
|
2021
Q2 | $38.9M | Sell |
1,516,738
-16,584
| -1% | -$395K | ﹤0.01% | 2863 |
|
|
2021
Q1 | $52.4M | Buy |
1,533,322
+468,576
| +44% | +$16.9M | ﹤0.01% | 2582 |
|
|
2020
Q4 | $36M | Buy |
1,064,746
+402,336
| +61% | +$10.7M | ﹤0.01% | 2681 |
|
|
2020
Q3 | $16.3M | Buy |
+662,410
| New | +$17.8M | ﹤0.01% | 2975 |
|
Other funds holding ITOS
BlackRock's ITOS Position: Q3 2025 in Review
BlackRock sold out of iTeos Therapeutics (ITOS) in Q3 2025, closing a stake of 4,574,537 shares — an estimated $45.6M sold.
BlackRock first reported a position in ITOS in Q3 2020 and held it in 20 quarters. The position peaked at $107M in Q1 2022. 1 fund tracked by Wall St. Rank holds ITOS as of Q3 2025.
- BlackRock reported no remaining iTeos Therapeutics position as of Q3 2025 after selling out during the quarter.
- BlackRock sold 4,574,537 iTeos Therapeutics shares in Q3 2025, an estimated $45.6M.
- BlackRock first reported a position in iTeos Therapeutics in Q3 2020 and held it in 20 quarters.
- BlackRock's iTeos Therapeutics position peaked at $107M in Q1 2022.
- 1 fund tracked by Wall St. Rank held iTeos Therapeutics as of Q3 2025.
Based on BlackRock's 13F filing for Q3 2025, filed 12 Nov 2025.